| Cat. No. |
Product Name |
Information |
| PC-35401 |
BET inhibitor CF53
BET inhibitor
|
BET inhibitor CF53 is a highly potent, orally active inhibitor of bromodomain and extra-terminal (BET) with Ki of <1 nM (BRD4 BD1). |
| PC-35400 |
QCA276
BET inhibitor
|
QCA276 is a novel potent BET proteins inhibitor with IC50/Ki of 10/.3 nM, QCA276 is the BET ligand for PROTAC QCA570. |
| PC-35172 |
ABBV-744
BET BD2 inhibitor
|
ABBV-744 (ABBV744) is a highly potent and selective inhibitor of the BD2 domain of BET family proteins with IC50 of 4-18 nM for BD2 of BRD2, BRD3, BRD4 and BRDT. |
| PC-35097 |
ZL0454
BRD4 inhibitor
|
ZL0454 is a potent, highly selective small-molecule BRD4 inhibitor with IC50 of 49 and 32 nM for BRD4-BD1 and BRD4-BD2, respectively. |
| PC-35096 |
ZL0420
BRD4 inhibitor
|
ZL0420 (ZL-0420) is a potent, highly selective BRD4 inhibitor with IC50 of 27 and 32 nM for BRD4-BD1 and BRD4-BD2, respectively. |
| PC-35015 |
JQ1-Az
|
JQ1-Az is a JQ1 derivative for PROTAC synthesis. |
| PC-63576 |
GSK8814
ATAD2/2B inhibitor
|
GSK8814 is a potent, selective inhibitor of ATAD2/2B bromodomain binding constant pKd of 8.1 in ITC assays. |
| PC-63543 |
CBP bromodomain inhibitor 17
CBP bromodomain inhibitor
|
CBP-IN-17 is a potent, selective CBP bromodomain inhibitor with IC50 of 69 nM, displays exquisite selectivity over BRD4(1) (IC50=18 uM) and the broader bromodomain family. |
| PC-63487 |
GSK-340
BET BD2 inhibitor
|
GSK-340 is a potent, selective inhibitor of second bromodomains of the BET family (BD2) with pKd of 8.18, 7.49, 7.72 and 7.68 for BRD4 BD2, BRD3 BD2, BRD2 BD2 and BRD4T BD2, respectively. |
| PC-63272 |
INCB057643
BET inhibitor
|
INCB057643 is a novel potent, selective, orally bioavailable BET inhibitor, reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. |
| PC-63255 |
SJ830599
|
SJ830599 is a modest selective BRD2-BD2 inhibitor with IC50 of 0.61 uM, 3.3-fold selectivity over BRD2-BD1. |
| PC-63245 |
Y08060
BET inhibitor
|
Y08060 is a potent and selective BET inhibitor with Kd of 306 nM for BRD4 BD1, displays excellent selectivity for BET subfamily over other non-BET family with the exception of moderate inhibition of CBP/EP300. |
